Medical Therapeutics

DNA Nanobots, LLC

Brief Description

With a portfolio of existing IP, DNA Nanobots develops products for targeted therapeutics and functionalized gene delivery. We have a dual approach, building partnerships to provide development expertise in the functionalization of DNA nanotechnology with experience in Gene Delivery, Vaccine Development, Targeted Drug Delivery, Biosensing, Immunotherapy, and Drug Discovery.

Timeline 2021. Company founded. Inventors

Jennifer Doudna, Enrique Lin Shiao, Rachael Lew

Intellia

Brief Description

Intellia is a leading genome editing company focused on the development of proprietary, potentially curative therapeutics utilizing a recently developed biological tool known as the CRISPR/Cas9 system. Intellia leverages leading scientific expertise, clinical development experience, and intellectual property position to unlock broad therapeutic applications of CRISPR/Cas9 genome editing and develop a potential new drug class.

Timeline 2014. Company founded. Inventors

Jennifer Doudna, Emmanuelle Charpentier, James Doudna Cate, Krzysztof...

Magnetic Insight

Brief Description

Magnetic Insight is developing solutions in Magnetic Particle Imaging (MPI), a ground-breaking technology that will overcome major deficiencies with current clinical and translational research imaging techniques.

Magnetic Insight Inc. was founded by one of the leading research groups in the global field of Magnetic Particle Imaging from UC Berkeley. Developed over the past decade in the research lab of UC Berkeley Bioengineering and Electrical Engineering and Computer Science Professor Steven Conolly, MPI has proven in animal studies to generate high-contrast...

Catena Biosciences

Brief Description

Cantena Biosciences uncovered a novel protein conjugation method that can bring breakthroughs in biological therapeutics, autoimmune disorders, and vaccine development.

Catena’s technology allows the attachment of any two proteins together faster and more selectively than any competing method by attaching the natural amino acids tyrosine and cysteine. Since the company's platform uses only naturally occurring amino acids, it is more widely applicable than competing technologies and can be used to create complicated constructs far beyond...

Mimesyn

Brief Description

Developing a novel class of molecules, aza-@-tides, that mimic the structural features of natural amino acids. These can be synthesized from amino acid precursors in either direction using standard peptide synthesis methods, facilitating the assembly of libraries incorporating all the amino acid building blocks.

Timeline 2004. Company founded Inventors

Paul Bartlett, Ming Chen Hammond, Stephen Olson, Scott Phillips, Miroslav Rezac

Vicinitas Therapeutics

Brief Description

Vicinitas Therapeutics is a biotechnology company focused on targeted protein stabilizers known as Deubiquituinase Targeting Chimeras (DUBTACs). The company’s mission is to use this proprietary technology to solve critical problems in human health by developing next-generation disease therapies against an entire class of previously inaccessible disease-causing proteins. The company spun out of technology that was developed through an academic-industry collaboration between UC Berkeley researchers and Novartis Institutes for BioMedical Research.

Timeline 2022...

GenoptX, LLC

Brief Description

A CRISPR-based gene editing company.

Formerly known as Syncodi.

Timeline 2019. Company founded. Inventors

Jennifer Doudna, Abraham Isser Flamholz, Dana Nadler, Benjamin Oakes, David Frank Savage

Geneditor Biosciences, Inc.

Brief Description

Geneditor Biosciences is a pre-clinical stage gene editing company focused on the treatment of rare cancers with unmet medical needs.

Timeline 2021. Company founded. Inventor

Jennifer Doudna

Evercrisp Biosciences

Brief Description

Evercrisp Biosciences is a biotechnology company engineering self-deliverable CRISPR genome editors intended to improve the area of oncology. The company focuses on the discovery and development of protein-based genome editors as therapeutics for multiple disease areas, enabling healthcare organizations to have novel enzymes with high cell permeability and editing efficiency.

Timeline 2021. Company founded. Inventor

Jennifer Doudna

Frontier Medicines Corporation

Brief Description

Frontier Medicines was founded to develop medical treatments for currently "undruggable" diseases. The clinical stage precision medicine company pioneers medicines for genetically-defined patient populations in oncology and immunology, and plans to broaden its therapeutic focus over time. The company uses chemoproteomics - an innovative approach to chemically interrogate proteins in living systems – to discover and pharmacologically target new binding pockets (or "hotspots") on proteins, making them accessible to small-molecule drug discovery and development. The...